Physician-led guidance brings your goals, health history and realistic expectations into one thoughtful plan.
The short answer
What is Tirzepatide for Medical Weight Management?
Tirzepatide activates GIP and GLP-1 receptors. FDA-approved Zepbound is indicated for chronic weight management in eligible adults, with additional labeled use for moderate-to-severe obstructive sleep apnea in adults with obesity, alongside nutrition and physical activity.
Concerns it may address
Obesity or overweight with qualifying weight-related conditions
Appetite regulation and sustained weight-management support
Obesity-related obstructive sleep apnea when the labeled criteria are met
Patients prepared for long-term monitoring and behavior change
Candidacy
Who may—or may not—be a candidate
Who may be considered
Eligibility depends on current labeling, BMI, related conditions, medications and risk profile. The prescriber confirms the indication, coordinates diabetes medicines and assesses gastrointestinal, gallbladder and thyroid history.
When treatment may not be appropriate
Tirzepatide is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2 and with serious hypersensitivity. Pregnancy and important gastrointestinal, pancreatic, gallbladder, kidney, eye and medication issues require review.
At a glance
Treatment facts
These are practical planning ranges, not promises. Your consultation determines the exact plan.
Treatment time
Initial visit about 30–60 minutes; follow-ups are shorter
Comfort / anesthesia
Weekly subcutaneous injection as prescribed
Typical downtime
No procedural downtime; gastrointestinal effects can limit activity
When changes may appear
Appetite or weight change evolves over weeks to months
How long results may last
Long-term therapy may be needed; weight regain can occur after stopping
Treatments commonly considered
Ongoing titration and monitoring
Your visit
What happens during treatment
Evaluate
The clinician reviews weight history, health conditions, medications, pregnancy plans and labs.
Plan & treat
If eligible, Zepbound or another appropriate FDA-approved product is prescribed and titrated according to labeling and tolerability.
Review & follow up
Weight, nutrition, strength, adverse effects and related conditions are monitored. The plan changes when benefit, risk or access changes.
Informed choice
Important risks, limitations and alternatives
Risks & limitations
Common effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort and injection-site reactions. Important risks include pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal effects, allergy and low blood sugar with certain diabetes drugs. Labeling includes a boxed thyroid C-cell tumor warning.
Alternatives to discuss
Intensive lifestyle and nutrition treatment
Semaglutide or another FDA-approved anti-obesity medication
Sleep-apnea treatment when indicated
Bariatric-surgery evaluation for eligible patients
Clinical judgment
Why provider experience matters
Safe care requires more than escalating a dose. Experienced supervision verifies sourcing, coordinates diabetes or sleep-apnea treatment, protects nutrition and lean mass, and recognizes when side effects or inadequate benefit require a change.
Identity Aesthetics approach
Diagnosis and anatomy before a product or device
Conservative planning with candid limitations
Licensed-provider supervision and complication readiness
In-office and telehealth boundaries stated clearly
Access & cost
In-office versus telehealth
Consultations and follow-up may be in-office or by telehealth for patients physically located in one of the 16 states we serve, subject to eligibility and law. Labs or in-person assessment may be required.
Pricing: Consultation required. Medication cost varies by product, insurance, pharmacy and dose. Coverage and availability cannot be guaranteed.
When a prescription or compounded preparation is clinically appropriate, the dispensing pharmacy, facility classification and current license status matter. Compounded medications are not FDA-approved drug products.
No. Compounded drugs are not FDA-approved. FDA has raised concerns about unapproved GLP-1 products, dosing errors and quality.
Is Mounjaro the same as Zepbound?
Both contain tirzepatide, but they have different FDA-approved indications and labeling. The prescribed product must match the diagnosis and treatment plan.
Can I combine tirzepatide with another GLP-1 drug?
Do not combine or switch medicines without prescriber direction. Zepbound labeling limits coadministration with other tirzepatide or GLP-1 products.
Medical-content evidence review: September 3, 2026. Content is written for patient education and structured from current primary regulatory, labeling and professional sources. It has not been individualized to your medical history. Product labeling and guidance can change; a licensed Identity Aesthetics provider confirms current suitability, informed consent and treatment details before care.
Your next step
Make an informed plan
Bring your goals, questions, medication list and prior treatment history. We will help you decide whether Tirzepatide for Medical Weight Management—or an alternative—makes sense.